Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 11/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 8/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.40 |
| ▸ | AURKA | O14965 | 6/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1319497 | 0.88 | CYP11B1 (0.44) | KDM1ACYP11B1CYP11B2PDPK1AURKB | |
| SCHEMBL1317162 | 0.88 | CYP11B1 (0.43) | KDM1ACYP11B1CYP11B2PDPK1AURKB | |
| SCHEMBL1317616 | 0.87 | KDM1A (0.43) | KDM1ACYP11B1CYP11B2PDPK1AURKB | |
| SCHEMBL1317305 | 0.87 | KDM1A (0.43) | KDM1ACYP11B1CYP11B2PDPK1AURKB | |
| SCHEMBL1320358 | 0.87 | KDM1A (0.43) | KDM1ACYP11B1CYP11B2PDPK1AURKB | |
| SCHEMBL1317948 | 0.87 | PDPK1 (0.43) | KDM1ACYP11B1CYP11B2PDPK1AURKB | |
| SCHEMBL1318556 | 0.84 | PDPK1 (0.42) | KDM1ACYP11B1CYP11B2PDPK1AURKB | |
| SCHEMBL1318149 | 0.83 | PDPK1 (0.49) | KDM1ACYP11B1CYP11B2PDPK1AURKB | |
| SCHEMBL12122325 | 0.81 | KDM1A (0.51) | KDM1ACYP11B1CYP11B2PDPK1 | |
| SCHEMBL16966526 | 0.81 | PDPK1 (0.53) | KDM1ACYP11B1CYP11B2PDPK1AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2362775-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-8697685-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| EP-2362775-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275611-A1 | CHEMICAL COMPOUNDS | PDK1, PDK2, PDK3 | KDM1A 1582/4885CYP11B1 634/4885CYP11B2 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.